Connect
← Return to Anyone with BRCA 2 mutation taking Olaparib?
Discussion
Anyone with BRCA 2 mutation taking Olaparib?
Pancreatic Cancer | Last Active: Oct 3 7:41pm | Replies (13)Comment receiving replies
stageivsurvivor, Was your cancer pancreatic cancer? Also, was it ductal cell pancreatic cancer or acinar cell pancreatic cancer? I'm presently in a clinical trial at the NIH in MD for use of Olaparib for my acinar cell pancreatic cancer. There was some fatique when I first started on the Olaparib about 6 wks. ago, but it has dissipated some now. My RBC and WBC were normal in the 2 blood tests I've had at the NIH so far. Creatinine was slightly out of limits, but increasing water intake per my NIH doc's instructions seems to have cleared that up. Anindita, it is my understanding that without having the BRCA 2 mutation Olaparib is ineffective. There are very good reasons for that but you'll have to do some research on the subject to understand it. I'm a retired airline mechanic and don't consider my qualified, or it being proper, for me to try to explain the way the drug works here. I was hanging on by my toenails to get the gist of it when my NIH docs explained it to me. I am wishing good luck and healing to your Dad.
Replies to "stageivsurvivor, Was your cancer pancreatic cancer? Also, was it ductal cell pancreatic cancer or acinar cell..."
Thanks a lot.!! @56pan
I wish you to be in best of your health soon..!! 🙂
Connect
I know of the trial you are in conducted by Christine Alewine MD at the NCI. I had a mixed tumor type of predominately acinar cell type with PDAC cells also found. The dysplasia of the acinar cells was poorly differentiated, high grade, 11/22 lymph nodes positive, perineural and peripancreatic invasion of the soft tissue. Also evaluated as PanIN1. Doesn’t get much worse than that.
It is well documented that PARP’s transiently and not permanently affect eGFR and creatinine. I drank copious amounts of water prior to each blood test to try and lower it. It had nothing to be with needing more hydration. I’ve been on Rubraca almost 10 years and in the few pauses I had, my eGFR and creatinine values have always returned to normal. It has not impaired my kidney function and I note my care team are concerned when those parameters are increased while in the drug. It causes more creatinine to be retained. Sometimes patients are incorrectly classified as stage IIIa renal disease in a rush to judgement.
Three of the most experienced oncologists in the country treating aBRCA mutations in pancreatic cancer are Eileen O’Reilly MD of MSKCC and Kim Reiss Binder MD at PennMedicine who have treated several ACC patients and Susan Domchek, MD-head of the Basser Center for BRCA at Penn Medicine and conducted the first pilot study of using a PARPi (Olaparib) in pancreatic cancer patients. All three are very familiar with my case and have been following it for almost 10 years now.